Literature DB >> 31931083

Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes.

Caroline A Nelson1, Sean Singer2, Tianqi Chen3, Ashleigh Eberly Puleo4, Christine G Lian5, Erin X Wei2, Anita Giobbie-Hurder3, Arash Mostaghimi2, Nicole R LeBoeuf6.   

Abstract

Entities:  

Keywords:  Autoimmune; BP; ICI; PD-1; PD-L1; blistering; bullous pemphigoid; cancer; dAE; dermatologic adverse event; immune checkpoint inhibitor; immunotherapy; nivolumab; oncodermatology; oncology; pembrolizumab; programmed death ligand-1; programmed death-1

Year:  2020        PMID： 31931083     DOI： 10.1016/j.jaad.2019.12.068

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  10 in total

Review 1.  Skin Manifestation Induced by Immune Checkpoint Inhibitors.

Authors:  Toshiyuki Yamamoto
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-05-10

Review 2.  Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.

Authors:  Aikaterini Tsiogka; Johann W Bauer; Aikaterini Patsatsi
Journal:  Acta Derm Venereol       Date:  2021-01-20       Impact factor: 3.875

Review 3.  Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.

Authors:  Taku Fujimura; Setsuya Aiba
Journal:  Biomolecules       Date:  2020-07-22

Review 4.  Treatment of Advanced Melanoma: Past, Present and Future.

Authors:  Taku Fujimura; Yumi Kambayashi; Kentaro Ohuchi; Yusuke Muto; Setsuya Aiba
Journal:  Life (Basel)       Date:  2020-09-16

5.  Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.

Authors:  Christian D Sadik; Ewan A Langan; Ralf Gutzmer; Maria Isabel Fleischer; Carmen Loquai; Lydia Reinhardt; Friedegund Meier; Daniela Göppner; Rudolf A Herbst; Detlef Zillikens; Patrick Terheyden
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

6.  Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit.

Authors:  Yung-Tsu Cho; Yi-Tsz Lin; Che-Wen Yang; Chia-Yu Chu
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

7.  "Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management.

Authors:  Pietro Sollena; Simone Cappilli; Francesco Federico; Giovanni Schinzari; Giampaolo Tortora; Ketty Peris
Journal:  Hum Vaccin Immunother       Date:  2021-03-24       Impact factor: 4.526

8.  A 72-year-old man with nonhealing facial erosions and bullae.

Authors:  Catherina X Pan; Catherine E Pisano; Mia S DeSimone; Vinod E Nambudiri
Journal:  JAAD Case Rep       Date:  2022-07-20

Review 9.  Bullous Pemphigoid: Trigger and Predisposing Factors.

Authors:  Francesco Moro; Luca Fania; Jo Linda Maria Sinagra; Adele Salemme; Giovanni Di Zenzo
Journal:  Biomolecules       Date:  2020-10-10

10.  Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Authors:  Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Journal:  Dermatopathology (Basel)       Date:  2022-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.